RELA and gastric cancer: Indeed, intraperitoneal administrations of RelA siRNA or nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor and an NF-κB inhibitor, in addition to paclitaxel were effective for suppressing peritoneal metastasis and increased survival time of mice with gastric cancer [170,171].